Oncology Medical News about Malignant peripheral nerve sheath tumor, EGFR

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Expression and significance of EGFR in malignant peripheral nerve sheath tumor
Journal of Neuro-Oncology, 08/12/09

Keizman D et al. - In a study to investigate the expression and prognostic influence of epidermal growth factor receptor (EGFR) in malignant peripheral nerve sheath tumor (MPNST), it seems that EGFR appeared to play a role in MPNST progression. EGFR overexpression was correlated with worse prognostic variables and course. Clinical trials of targeting EGFR in MPNST are warranted.

Methods

Primary and metastatic MPNSTs were immunostained with antibodies to EGFR.
The total EGFR expression (membranous and cytoplasmic) was analyzed by morphometry, grade of positivity and intensity (score 0–3).
An EGFR composite score (range 0–300) was calculated by multiplying intensity by the grade; a composite score >10 was considered as EGFR overexpression.
Score was correlated with clinical behavior.

Results

43% of 46 pts with MPNST overexpressed EGFR in the primary tumor, and had a higher prevalence of advanced-stage tumors (≥IIc, 46% vs 80%).
Pts without overexpression had a higher prevalence of tumors with a low mitotic rate (31% vs 0%).
Neurofibromatosis was more prevalent in pts with EGFR overexpression (75% vs 42%).
5-yr disease-free survival (mean 30.1 vs 17.4 mos), time to progression (mean 9.2 vs 5.2 mos) and 5-yr survival (52% vs 25%, mean 54 vs 43 mos) were significantly higher among pts without overexpression.

<< Previous
Prolonged low-dose administration of the cyclooxygenase-2...

Next >>
Alternations of ER, PR, HER-2/neu, and P53 protein expression in...